DNAnexus Appoints David Shaywitz as Chief Medical Officer

Experienced healthcare executive will lead strategy and business development activities supporting the company's patient-inspired vision of genome-enabled medicine

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, a leader in enterprise solutions for networked genome informatics and data management, today announced the expansion of its senior leadership team with the appointment of David Shaywitz, M.D., Ph.D. as the company's first Chief Medical Officer. Shaywitz joins DNAnexus from Theravance Biopharma and will focus on leveraging the company's pioneering cloud-based genomics platform to drive clinical impact, working closely with management and engineering teams, and with external partners and collaborators.

"The future of healthcare will require the ability to rapidly absorb, seamlessly integrate, and thoughtfully analyze a deluge of healthcare data flows, starting with the human genome"
"We're delighted to welcome David to the DNAnexus team," said Richard Daly, CEO of DNAnexus. "His passion for innovation, his commitment to patients and to high-quality science, and his sophisticated understanding of the healthcare space, represent an outstanding fit with the DNAnexus team and vision."

At Theravance Biopharma, Shaywitz focused on strategy and business development, and led a product team. Prior, he was a management consultant at the Boston Consulting Group, and was an early member of the Department of Experimental Medicine at Merck Research Labs.

Shaywitz received his M.D. from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his Ph.D. from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton's lab in the Harvard Stem Cell Institute.

Shaywitz is also a co-founder of the PASTEUR translational research program at Harvard Medical School, a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH), where he continues to serve as West Coast Innovation Lead. He is also co-author with Lisa Suennen of "Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology?" (Hyperink, 2013).

"The future of healthcare will require the ability to rapidly absorb, seamlessly integrate, and thoughtfully analyze a deluge of healthcare data flows, starting with the human genome," Shaywitz said. "The DNAnexus platform provides a cost-effective, secure, and regulatory compliant foundation upon which this vision can be constructed and ultimately realized."

About DNAnexus

DNAnexus is powering the genomics revolution with an enterprise-level solution that combines cloud computing with advanced bioinformatics. The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to establish DNAnexus at the center of a growing ecosystem of scientific and clinical research, and diagnostic efforts in personalized medicine. For more information please visit: https://dnanexus.com.


Media Contact:
for DNAnexus
Colin Sanford, 203-918-4347
[email protected]

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.